Farley Joel F, Kumar Arun, Urick Benjamin Y
Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Center for Medication Optimization, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Pharmacy (Basel). 2019 Jul 2;7(3):81. doi: 10.3390/pharmacy7030081.
Adherence to renin angiotensin system antagonists (RASA), non-insulin diabetes medications (NIDM) and statins has been included in the Medicare Star Ratings program since 2012. The long-term use of these measures emphasizes adherence to a limited number of chronic medications and may present opportunities for Part D plan sponsors to misuse the measures to influence their Medicare Part D Star Rating. It also does not capture the adherence needs of high-risk patients with multiple chronic conditions. The objective of this study was to describe the development of a new measure to capture adherence to multiple medications for chronic conditions (MMCC). The MMCC measure captures adherence to 71 different therapeutic categories of medication and was constructed using North Carolina Medicaid prescription claims data from 2015 to 2017. This measure was validated against the existing RASA, NIDM and statin adherence measures. This new measure was highly correlated with Star Rating measures, captured a greater number of eligible patients than these existing measures and had a lower proportion of patients meet the adherence threshold than the existing Star Ratings adherence measures. There is an opportunity to develop new measures, which include adherence to multiple medications in populations with multiple chronic conditions.
自2012年起,肾素血管紧张素系统拮抗剂(RASA)、非胰岛素糖尿病药物(NIDM)和他汀类药物的依从性已被纳入医疗保险星级评定计划。长期使用这些指标强调对有限数量的慢性药物的依从性,可能会让D部分计划赞助商有机会滥用这些指标来影响他们的医疗保险D部分星级评定。它也没有考虑到患有多种慢性病的高危患者的依从性需求。本研究的目的是描述一种新指标的开发,以衡量对多种慢性病药物(MMCC)的依从性。MMCC指标涵盖了71种不同治疗类别的药物,是利用北卡罗来纳州医疗补助处方索赔数据(2015年至2017年)构建的。该指标与现有的RASA、NIDM和他汀类药物依从性指标进行了验证。这项新指标与星级评定指标高度相关,比现有指标涵盖了更多符合条件的患者,并且达到依从性阈值的患者比例低于现有的星级评定依从性指标。有机会开发新的指标,其中包括患有多种慢性病的人群对多种药物的依从性。